IgD multiple myeloma: biology, diagnosis, and treatment

IgD multiple myeloma is uncommon. Patients generally present at a younger age and have shorter progression free and overall survivals (OSs). Its rarity has inhibited development of a specific risk stratification system or informed best treatment protocols. We present interphase fluorescence in situ...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma Vol. 63; no. 14; pp. 3433 - 3437
Main Authors: Egan, Philip A., O'Connor, Sheila J. M., Deighan, W. Ian, McConville, Conal E., Elder, Patrick T., (Curly) Morris, T. C. M., Alexander, H. Denis
Format: Journal Article
Language:English
Published: United States Taylor & Francis 06-12-2022
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IgD multiple myeloma is uncommon. Patients generally present at a younger age and have shorter progression free and overall survivals (OSs). Its rarity has inhibited development of a specific risk stratification system or informed best treatment protocols. We present interphase fluorescence in situ hybridization results from a group of 29 cases. These showed evidence of a decreased male to female ratio, decreased OS in patients aged 70 and over, better outcomes in those with kappa light chain restriction, and CD56 positive patients had longer survivals than those lacking CD56. We discuss the biology of IgD multiple myeloma, the need for prospective studies, and challenges for improvements in diagnosis and treatment. We suggest an International Register to accelerate development of best practice guidelines for diagnosis, risk stratification, and treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2022.2126280